Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semzuvolimab - United Biopharma

Next Previous
X
Search
Drug Profile

Semzuvolimab - United Biopharma

Alternative Names: dB4; dB4C7 mAb; dB4C7C22-6 mAb; mAb B4; UB-421

Latest Information Update: 04 Jan 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator United Biomedical
  • Developer Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans General Hospital; United Biomedical; United BioPharma
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 04 Jan 2024 Semzuvolimab is still in phase III trials for HIV-1 infections in Taiwan, China, Thailand
  • 25 Apr 2023 United Biopharma withdraws a phase III trial prior to enrolment due to project adjustment for HIV-1 infections (Monotherapy) in China (IV) (NCT03149211)
  • 01 Feb 2023 United BioPharma completes a phase II trial for HIV-1 infection (Treatment experienced, Monotherapy, Combination therapy) (NCT05056974)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top